LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections

SCHLIEREN, Switzerland, October 09, 2023--LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against increasingly dangerous bacterial infections, including programs addressing shigellosis and gonorr

Related Keywords

United States ,New York ,Switzerland ,London ,City Of ,United Kingdom ,Alexander Siebert ,Kabeer Aziz ,Zina Affas Besse ,Limmatech Biologics ,Franz Werner Haas ,Camilla Petrycer Hansen ,Hooft Van Huijsduijnen ,Limmatech Bio ,Novo Holding ,Principal At Novo Holdings ,Impact Fund ,National Overview ,Infective Resistance Impact Fund ,Novo Holdings ,Novo Nordisk Foundation ,World Health Organization ,Trophic Communications ,United States Centers For Disease ,Adjuvant Capital ,Affas Besse ,Deputy Head ,Private Equity ,Petrycer Hansen ,Antimicrobial Resistance ,United States Centers ,Disease Control ,Anti Infective Resistance ,Novo Nordisk ,Resistance Collaborators ,Retrieved August ,Exploring Shigella ,Werner Haas ,Bacterial Infections ,Vaccine Development ,Iologics Ag ,Ovo Holdings Repair Impact Fund ,Global Health ,Vaccine Candidates ,Clinical Development ,Adjuvant ,Arsenal ,